MIVS technique continues to evolve

Article

Retinal surgeons refine technology, instrumentation to optimize safety and efficacy

Microincision vitrectomy surgery (MIVS) is changing the way that vitreoretinal specialists operate. As with any new technology, MIVS has a number of significant advantages, as well as a few new challenges.

Overall, patients come in on postoperative day 1 usually with minimal to no discomfort and they are not usually troubled by slowly dissolving Vicryl sutures rubbing under their eyelids for two weeks. Because the incisions into the conjunctiva are smaller, there is less bleeding, which results in a better cosmetic appearance (still not as good as after cataract surgery, but for a retina surgeon, it is pretty good).

From the surgeon's perspective, there are a number of advantages to MIVS. For most cases, MIVS is faster than standard 20 G vitrectomy. With the previous-generation MIVS systems, especially 25 G, vitrectomy removal took longer, but the time saved in opening and closing the eye made the overall surgical time for 'straight-forward' cases about the same or somewhat less than 20 G vitrectomy.

The new-generation MIVS systems offer 5,000 cuts-per-minute. The surgeon is able to remove the vitreous remarkably efficiently, and the vitrectomy time is better than with standard 20 G vitrectomy. For those accustomed to 20 G systems, a 20 G 5,000 cuts-per-minute probe is available, but given how efficient the MIVS systems are at this rate, 20 G vitrectomy does not distinguish itself.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.